The global diabetes epidemic continues to worsen, and diabetes has become one of the leading diseases causing human deaths. Data show that the number of people with diabetes worldwide reached 366 million in 2011, and on average, one person dies from the disease every seven seconds in the world. On October 16 of this year, the “China Type 2 Diabetes Prevention and Treatment Guidelines” were officially released in Beijing, revising the glycemic control goals, emphasizing comprehensive treatment and prevention of cardiovascular lesions, developing new diagnosis and treatment procedures, and reflecting new advances in treatment. Epidemiological data in recent years show that the incidence of diabetes in China is about 9.7%, and the number of diabetic patients is as high as more than 92 million, ranking first in the world. Only 1/4 of diabetic patients in China meet the standard, and 60.7% of diabetic patients are undiagnosed. The new version does not recommend the current diagnosis of diabetes with glycosylated hemoglobin in China, and the glycosylated hemoglobin control standard has been changed to 7%. The target of blood glucose control: fasting blood glucose control range is 3.9-7.2 mmol/L, non-fasting bedtime blood glucose <10.0 mmol/L, glycosylated hemoglobin <7.0%; in addition, the bedtime blood glucose level should not be <6.0 mmol/L, and the nighttime blood glucose value should not be <5.0 mmol/L at 3 o'clock. The new edition no longer distinguishes between obese or non-obese patients, but unifies the diabetes treatment drugs Distinguished by the order of medication, classified by first-line, second-line, third-line and fourth-line, as the step of selecting therapeutic drugs, and with lifestyle interventions throughout the treatment. To enable pancreatic u-insulin therapy, the new version proposes recommendations are: 1. newly diagnosed type 2 diabetes with glycosylated hemoglobin ≥ 9.0% and significant diabetic symptoms; 2. blood glucose failure (glycosylated hemoglobin > 7.0%) after 3 months of treatment with effective lifestyle interventions and two or more oral hypoglycemic agents; and 3. weight loss without a definite cause during the course of the disease. In recent studies, for newly diagnosed type 2 diabetic patients, short-term (about 2 weeks) intensive insulin therapy can enable half of the patients to achieve more than 1 year of glycemic control through lifestyle interventions alone. For newly diagnosed type 2 diabetic patients, especially those with significantly elevated blood glucose (fasting blood glucose >11.1 mmol/L), short-term intensive insulin therapy can be considered first, so as to clear glycolipotoxicity as soon as possible and allow the beta cells of the pancreas to fully “rest” and save the remaining beta cell function to the maximum extent. The new version proposes a standard treatment for diabetic patients that emphasizes lipid-lowering, blood pressure-lowering and anticoagulation, which plays a great role in improving the prognosis.